ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Three Year Post Co-Stimulation Blocking Agent (Belatacept) Switch Outcomes of Kidney Transplant Patients Diagnosed with Post-Transplant Thrombotic Microangiopathy

A. Gamilla-Crudo, S. Hussain, A. Rizvi, R. Ramirez, M. Kueht, H. Stevenson-Lerner, J. Fair, M. Mujtaba

UTMB, Galveston, TX

Meeting: 2020 American Transplant Congress

Abstract number: 113

Keywords: Co-stimulation, Kidney transplantation, Nephrotoxicity, Renal injury

Session Information

Session Name: Novel Immunosuppression: Belatacept

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:51pm-4:03pm

Location: Virtual

*Purpose: Thrombotic microangiopathy (TMA) can happen after kidney transplant. It may occur de novo or as a recurrent disease. De novo is usually associated with immunosuppressive drugs such as calcineurin inhibitors (CNI) and sirolimus, or can be seen as part of endothelial damage that accompanies antibody-mediated rejection (AMR). Treatment for de novo TMA is limited to plasma exchange and change in immunosuppression and in extreme cases, addition of Eculizumab. Belatacept is a co-stimulation blocking agent and considered least nephrotoxic, and may provide an immunosuppression option in patients with post-transplant TMA.

*Methods: A retrospective review of prospectively collected data was conducted on kidney transplants from 2013 to 2019. 45 kidney transplant patients were switched from CNI to Belatacept due to concerns of TMA. Seventy percent of the patients had kidney biopsy proven changes of TMA. We report their outcomes post switch. Continuous variables are being reported as mean with SD. A paired t-test was used and P value of <0.05 was considered to be significant.

*Results: Majority of patients were Hispanic with age 54Y± 11.9, 55% were females. Post belatacept switch follow up on these patients was 37+/- 15 months. Significant improvement in pre and post switch serum creatinine (p=0.0001) and urine protein/creatinine (0.006) was observed. 14 patients had detectable donor specific antibodies (DSA) at the time of switch, out of these four patients were still positive at last follow up, whereas two new patients developed DSAs. Four (8%) patients developed acute cellular rejection, and one (2%) patient had AMR. One patient died due to infectious complications at 9 months post-transplant, and one patient lost her kidney allograft at 30 months post switch due to non-resolving AMR. Three year death censored graft survival in these patients is 97.7%.

 border=

*Conclusions: Belatacept appears to be a useful alternative immunosuppressive agent in kidney transplant patients with TMA without increasing the risk of rejection or infection. Switching maintenance immunosuppression to Belatacept will likely result in a significant improvement in renal outcome.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Gamilla-Crudo A, Hussain S, Rizvi A, Ramirez R, Kueht M, Stevenson-Lerner H, Fair J, Mujtaba M. Three Year Post Co-Stimulation Blocking Agent (Belatacept) Switch Outcomes of Kidney Transplant Patients Diagnosed with Post-Transplant Thrombotic Microangiopathy [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/three-year-post-co-stimulation-blocking-agent-belatacept-switch-outcomes-of-kidney-transplant-patients-diagnosed-with-post-transplant-thrombotic-microangiopathy/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences